About Endotis Pharma
Endotis Pharma is a Healthcare company based in Romainville (France) founded in 2003. Small Glycan Drugs (SGDs) to treat cardiovascular diseases. Endotis Pharma has raised $41.13 million across 2 funding rounds from investors including Wellcome, Endeavour Vision and Sofinnova. Its Indian entity Ironsource India Private Limited reported revenue of ₹21.75 Cr. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified.
Company details
As of October 25, 2012, Endotis Pharma SA is in liquidation. The company specialized in the discovery and development of small glycan drugs (SGDs) for cardiovascular diseases. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology. Through internal research and in-licensing, Endotis had developed a pipeline including EP217609, a neutralizable anticoagulant for managing extracorporeal blood circulation during open-heart surgery; fondaparinux (Arixtra), a reference injectable drug for the prevention and treatment of venous thromboembolism; and an oral antidotable anticoagulant for stroke prevention in atrial fibrillation.
- Headquarters Romainville, France
- SectorsHealthcare
- Website endotis.com
- Social LinkedIn
- Legal Name Ironsource India Private Limited
- Date of Incorporation 26 Apr, 2016
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹21.75 Cr
FY 2025 · +206% YoY
- Indian entity net profit₹3.79 Cr
FY 2025 · 17% margin
- Indian entity EBITDA₹5.88 Cr
FY 2025 · 27% margin
- Total Equity Funding$41.13M (USD)
in 2 rounds
- Latest Funding Round$36.22M (USD), Series B
Jan 2008
- InvestorsWellcome
& 2 more
Associated legal entities of Endotis Pharma
Endotis Pharma operates through Ironsource India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ironsource India Private Limited CIN U74300KA2016FTC092539 | Active | 26 Apr 2016 | Bangalore, Karnataka | ₹21.7 Cr | 21 | 4 | View details |
Funding Insights of Endotis Pharma
Endotis Pharma has successfully raised a total of $41.13M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $36.22 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41.13M
- Total Rounds 2
- Last Round Series B — $36.22M
- First Round $4.92M
(Jun 2005)
- Investors Count 3
All 2 funding rounds of Endotis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2008 | $36.22M | Series B | – | Wellcome Trust | |
| Jun 2005 | $4.92M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Endotis Pharma
Endotis Pharma has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Wellcome, Endeavour Vision and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Endeavour Vision is focused on transformative healthcare technology investments. | endeavourvision.com | Geneva, Switzerland | ||
Life Sciences sector focused early stage VC firm investing primarily in Europe | sofinnova.fr | Paris, France | ||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom |
Investor details for Endotis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ironsource India Private Limited (Endotis Pharma)
Ironsource India Private Limited is the primary company behind Endotis Pharma. The board of Ironsource India Private Limited currently have 4 directors; the longest-serving is Nora Sen Go, appointed in 2024. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Nora Sen Go DIN 10531941 | Director | 04 Mar 2024 | 2 yrs 8 mo | Ironsource India Private Limited |
| Bhagavant Bedi DIN 08005696 | Director | 21 Nov 2024 | 1 yr 11 mo | Ironsource India Private Limited |
| Jasmine De Layton DIN 10792925 | Director | 08 Jul 2025 | 1 yr 4 mo | Ironsource India Private Limited |
| Shridhar Subbaraman Iyer DIN 07151577 | Director | 30 Oct 2025 | 1 yr | Ironsource India Private Limited |
Financials of Endotis Pharma
Figures of Ironsource India Private Limited, the primary company behind Endotis Pharma, for FY 2025. Revenue was ₹21.75 Cr (+206% year on year). Net profit was ₹3.79 Cr (17% margin). EBITDA was ₹5.88 Cr (27% margin). Revenue has grown at a compounded annual rate of +87% over three years and +59% over five years.
- ₹21.75 CrRevenue · FY 2025 · +206% YoY
- ₹3.79 CrNet profit · 17% margin
- ₹5.88 CrEBITDA · 27% margin
- ₹1 LakhPaid-up capital
- 21Employees (provident fund records)
- +87%Revenue CAGR, 3 years
- +59%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ironsource India Private Limited are on its company page.
Detailed financial statements for Endotis Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Endotis Pharma
3 dated milestones of Endotis Pharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Endotis Pharma is founded.
- Funding First funding round of $4.9M.
- Funding Latest funding round, Series B, of $36.2M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Endotis Pharma
Complete news archive for Endotis Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endotis Pharma
Endotis Pharma was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Endotis Pharma is headquartered in Romainville, France. It is registered at Romainville, Ile-de-france, France.
Endotis Pharma is a funded company, having raised a total of $41.13M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.92M, raised on Jun 2005.
The primary company behind Endotis Pharma, Ironsource India Private Limited, reported revenue of ₹21.75 Cr for FY 2025, up 206% year on year.
As of October 25, 2012, Endotis Pharma SA is in liquidation. The company specialized in the discovery and development of small glycan drugs (SGDs) for cardiovascular diseases. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology. Through internal research and in-licensing, Endotis had developed a pipeline including EP217609, a neutralizable anticoagulant for managing extracorporeal blood circulation during open-heart surgery; fondaparinux (Arixtra), a reference injectable drug for the prevention and treatment of venous thromboembolism; and an oral antidotable anticoagulant for stroke prevention in atrial fibrillation.
Endotis Pharma has 3 investors. Key investors include Wellcome, Endeavour Vision, and Sofinnova.
Endotis Pharma operates through Ironsource India Private Limited.
The legal entities of Endotis Pharma currently have 4 directors, including Nora Sen Go, Bhagavant Bedi, Shridhar Subbaraman Iyer and others.